



## A rising tide of type 2 diabetes in younger people: what can primary care do?

An increasing incidence of early onset type 2 diabetes in New Zealand is putting more people at risk of complications and early mortality. Primary healthcare professionals should consider how they can use their role to identify young people at high risk and support them to create a different future.

### KEY PRACTICE POINTS:

- The incidence of type 2 diabetes in younger adults and adolescents in New Zealand is increasing; people of Māori, Pacific and South-Asian ethnicities are particularly at risk
- People with early onset type 2 diabetes have increased morbidity and mortality compared to those with a later onset or to those of similar age with type 1 diabetes
- Preventing, or delaying, onset of type 2 diabetes is paramount to reducing the burden of diabetes complications; this may be possible with careful management
- Test HbA<sub>1c</sub> levels in patients at high risk, regardless of their age, so that patients and their whānau/family can be supported to make lifestyle changes before or soon after they develop diabetes
- The management of type 2 diabetes in younger people is essentially the same as for older people, i.e. lifestyle interventions and metformin first-line, but treatments need to be more assertive, e.g. pharmacological treatment escalated sooner
- A high degree of patient and whānau/family engagement is crucial to maximise the benefits of lifestyle changes and ensure that medicines are taken as prescribed

This is a revision of a previously published article.  
What's new for this update:


- Updated data on the estimated prevalence of type 2 diabetes in those aged 25 – 39 years
- Begin CVD risk assessment, including HbA<sub>1c</sub>, at age 25 years for people with severe mental illness
- Updated recommendations on screening and management of type 2 diabetes in children and adolescents

## Early onset type 2 diabetes: increasingly common and associated with higher risks

New Zealand has a diabetes problem, fuelled in part by one of the highest rates of obesity in the world.<sup>1</sup> Approximately 5% of the total population has type 2 diabetes; this is predicted to increase to 7% of the population by 2040 (equating to an estimated 430,000 people with type 2 diabetes).<sup>2</sup> The prevalence of diabetes is highest in older age groups, reaching approximately 15 – 20% in people aged over 65 years; however, the prevalence is also increasing in younger people in New Zealand.<sup>3</sup> Data from the Ministry of Health’s Virtual Diabetes Register show the prevalence of type 2 diabetes\* in people aged 30 – 39 years has nearly doubled between 2006 and 2018 (Figure 1). Increases in diagnoses in children aged under 15 years have also been observed, although absolute numbers are still small.<sup>4</sup> People of Māori, Pacific and South-Asian ethnicity, and people who are socioeconomically disadvantaged, bear a disproportionate burden of obesity and type 2 diabetes. The prevalence of diabetes is approximately two to three times higher in adults aged 25 – 39 years of Māori and Pacific ethnicity compared to those of European ethnicity (Figure 2).

N.B. Increasing rates of type 2 diabetes may partially reflect greater awareness and testing over the years.

\* The Virtual Diabetes Register does not distinguish between type 1 and type 2 diabetes. Therefore, the prevalence of type 2 diabetes was estimated based on the assumed ratio of 90% type 2 diabetes to 10% type 1 diabetes;<sup>2</sup> this is a limitation when interpreting the data in younger age groups where type 1 diabetes is more prevalent.



**Figure 1.** Changes in the estimated prevalence of type 2 diabetes from 2006 to 2018 in adults aged 25 – 39 years in New Zealand. Source: Virtual Diabetes Register and Statistics NZ.

## Many young people are at high risk of developing type 2 diabetes


People with HbA<sub>1c</sub> levels of 41 – 49 mmol/mol are classified as having “pre-diabetes”, which is associated with an increased risk of cardiovascular disease and progression to type 2 diabetes. Data from the most recent national nutrition survey identified that 16% of the population aged under 45 years had pre-diabetes.<sup>5</sup> It is estimated that in the Auckland region, over 40% of people of Māori, Pacific or Indian ethnicity aged 35 – 39 years have pre-diabetes.<sup>3</sup>

## Early onset results in worse health outcomes

Younger people diagnosed with type 2 diabetes, e.g. before the age of 40 years, have a higher risk of early mortality, cardiovascular disease, chronic kidney disease and retinopathy than older adults diagnosed with type 2 diabetes or people with type 1 diabetes at a similar age.<sup>6–8</sup> This is largely because people diagnosed younger have diabetes for longer and are therefore exposed to more risk, but also because glycaemic control tends to be worse and younger people are more likely to have sporadic contact with healthcare services.<sup>6,9</sup>

## Test people at high risk

**HbA<sub>1c</sub> should be tested in people at high risk of type 2 diabetes of any age** to aid early detection and therefore reduce their risk of future cardiovascular and renal complications. As type 2 diabetes is not necessarily associated with any symptoms, patients may not even recognise that they are at risk.



**Figure 2.** The change in prevalence of diabetes in adults aged 25 – 39 years from 2006 to 2018, by ethnicity. Source: Virtual Diabetes Register and Statistics NZ.

## Identifying people at elevated risk

Ministry of Health guidelines recommend HbA<sub>1c</sub> testing in adults (age > 18 years) with **any** of the following risk factors:<sup>3</sup>

- A BMI of  $\geq 27$  kg/m<sup>2</sup> for people of Māori, Pacific or South Asian ethnicities, or  $\geq 30$  kg/m<sup>2</sup> for people of other ethnicities\*
- A first-degree relative who developed type 2 diabetes at an early age, e.g. < 40 years
- Long-term use of oral corticosteroids
- Females with a personal history of gestational diabetes
- Females with polycystic ovary syndrome
- Severe mental illness, particularly those on long-term antipsychotic treatment
- Known ischaemic heart, cerebrovascular or peripheral vascular disease

A specific opportunity to incorporate HbA<sub>1c</sub> testing into routine practice is the cardiovascular risk assessment; the age at which to start assessments is now recommended as:<sup>10</sup>

- 45 years for males and 55 years for females with no known risk factors


- 30 years for males and 40 years for females of Māori, Pacific or South-Asian ethnicity
- 35 years for males and 45 years for females with known cardiovascular risk factors or at high risk of developing diabetes†
- 25 years for people with severe mental illness

\* A lower BMI threshold is recommended for people of Māori, Pacific or South Asian ethnicities due to the higher risk people of these ethnicities have of developing type 2 diabetes.<sup>3</sup> South Asian ethnicities include Indian, Fijian Indian, Sri Lankan, Afghani, Bangladeshi, Nepalese, Pakistani and Tibetan. People of South or East Asian ethnicity may develop type 2 diabetes at lower BMI levels than people of European ethnicity, likely due to differences in the accumulation of visceral fat.<sup>11</sup>

† Further information on family and personal risk factors is available at: [www.health.govt.nz/publication/cardiovascular-disease-risk-assessment-and-management-primary-care](http://www.health.govt.nz/publication/cardiovascular-disease-risk-assessment-and-management-primary-care)

## Screening for type 2 diabetes in high-risk children and adolescents

Screening recommendations for type 2 diabetes in children and adolescents are guided by risk factors (Figure 3). A lower threshold for screening is recommended for Māori and Pacific children due to the higher rates of type 2 diabetes, obesity and CVD at younger ages in these groups.<sup>12</sup>



**Figure 3.** Type 2 diabetes screening recommendations for children and adolescents.<sup>12</sup>


Diagnosis of type 2 diabetes can be based on:<sup>12</sup>

- Symptoms of diabetes or hyperglycaemic crisis and a random plasma glucose  $\geq 11.1$  mmol/L
- Fasting plasma glucose  $\geq 7.0$  mmol/L
- 2-hour plasma glucose  $\geq 11.1$  mmol during an OGTT
- $\text{HbA}_{1c} \geq 50$  mmol/mol\*

\* The diagnostic threshold used in the Australasian guidelines is  $\text{HbA}_{1c} \geq 48$  mmol/mol, but it is generally accepted in New Zealand that diabetes is diagnosed at 50 mmol/mol

A screening frequency of two to three years is recommended, although earlier testing may be indicated in cases where there has been excessive weight gain.<sup>12</sup>

**Consider the possibility of type 1 diabetes or a monogenic form of diabetes** in children or younger adults with an elevated  $\text{HbA}_{1c}$  without obesity, a family history or other typical features such as hypertension, dyslipidaemia or non-alcoholic fatty liver disease. Its incidence peaks in children aged 10 – 19 years, but over half of cases are diagnosed in people aged over 20 years.<sup>13,14</sup> Monogenic diabetes is estimated to be present in up to 8% of children with features of type 2 diabetes.<sup>12</sup>


 An algorithm to help clinicians diagnose monogenic diabetes has been developed by the New Zealand Society for the Study of Diabetes: [www.nzssd.org.nz/resources-and-calculators.html](http://www.nzssd.org.nz/resources-and-calculators.html)

## Lifestyle change is a cornerstone of managing and reducing the risk of type 2 diabetes at all ages

One of the most important points to convey to people who have type 2 diabetes or pre-diabetes and their whānau/family is that the course is modifiable. Lifestyle changes, i.e. ensuring a healthy, balanced diet and engaging in regular physical exercise, may be difficult at first, but they can substantially improve their future health. The patient or their parent/caregiver will have to take the lead role in making those changes, but with support from their primary care team. Setting small, incremental goals can be helpful if patients are feeling overwhelmed by the extent of changes recommended.<sup>15</sup>


### Lifestyle recommendations for adults

**Weight loss has the potential to induce remission of type 2 diabetes** in people who are overweight or obese, i.e. to achieve an  $\text{HbA}_{1c} < 50$  mmol/mol without the use of medicines,<sup>16</sup> and should be regarded as a core focus of treatment.

 For further information on weight loss, see: Page 15 and [www.bpac.org.nz/2019/weight-loss.aspx](http://www.bpac.org.nz/2019/weight-loss.aspx)

**Lifestyle change in people with pre-diabetes** reduces their chance of developing diabetes by approximately 50 – 60% over three years and 27% over 15 years.<sup>17,18</sup> This includes aiming for a 5 – 10% weight loss, 2.5 hours per week of moderate intensity physical activity and following healthy diet recommendations.<sup>19</sup>

**Referral for bariatric surgery** may be appropriate for some people with a BMI between 35 – 55 kg/m<sup>2</sup> to assist with weight loss.<sup>15</sup> Bariatric surgery can reduce the likelihood of developing type 2 diabetes, and in those who already have type 2 diabetes, can induce remission, as well as reduce the risk of diabetes complications, cardiovascular disease and some cancers.<sup>15,20</sup> Māori and Pacific peoples may require more support to ensure they get bariatric surgery; fewer publicly funded bariatric surgeries are conducted for Māori or Pacific peoples than Europeans.<sup>21</sup> Research has shown there are higher rates of withdrawal prior to surgery in Māori and Pacific peoples.<sup>22</sup> Discussing potential barriers with patients can help them to prepare and plan ahead for some of the difficulties they may face if they are accepted for surgery. Regular follow-up contact is also likely to be helpful once a patient has been accepted for surgery.

 For further information on bariatric surgery, see: “Weight loss for the prevention and treatment of type 2 diabetes”, Page 15

### Lifestyle recommendations for children and adolescents

**Diet and weight management.** Ensure that the diet is nutritionally adequate for the child or adolescent’s growth and developmental stage.<sup>11</sup> The goal is to prevent further weight gain in those who are overweight and encourage weight loss in those who are obese, while maintaining normal linear growth.<sup>11</sup>

**Encourage physical activity.** At least 60 minutes per day of moderate to vigorous intensity exercise is recommended for children and adolescents, with strengthening exercises included three days per week.<sup>12</sup> Body weight exercises and light resistance bands or weights are appropriate for children; external resistance, e.g. gym equipment, can be added for adolescents who have reached skeletal maturity.<sup>12</sup>

**Reduce recreational screen time.** All children, including those with type 2 diabetes, should spend no more than two hours per day on recreational screen time, e.g. smartphones, tablets, computers, television; approximately four out of five children in the general population do not meet this target.<sup>12,23</sup>

**Ensure adequate sleep.** Children aged 5 to 13 years should be getting 9 – 11 hours of sleep per night; 8 – 10 hours of sleep per night is recommended for adolescents aged 14 – 17 years.<sup>12</sup>



Recommend sleep hygiene measures such as earlier and consistent bed and wake times, and reduced use of electronic media and devices at night.<sup>11</sup>

### Engaging people to make changes

**Identify what motivates people.** Reactions to a diagnosis of type 2 diabetes, or being told they are at high risk, can differ between people. Motivational strategies should be individualised, but a key message is that it is never too late to “step back from the edge” and the course of type 2 diabetes is not pre-determined.

**Avoid stigma and blame.** Discussing lifestyle changes can be challenging, as the advice required often carries an unspoken implication that the person has brought the disease on themselves or their child. Conveying that the risk of type 2 diabetes and obesity is influenced by factors which are out of a person’s control, e.g. genetics, exposures in utero or early childhood, or factors in the environment, may help alleviate some of the stigma and embarrassment associated with obesity and type 2 diabetes. Advice on language which can help avoid blame when discussing type 2 diabetes is provided in Table 1 (Page 56).


**Regular follow-up is essential.** Develop an agreed plan that can be used to track progress, e.g. appointment with a practice nurse, providing advice or support via telephone or text message. A randomised controlled trial in the United States found that participants who had completed a lifestyle intervention were less likely to regain weight if they had telephone follow up rather than written education alone.<sup>24</sup> Encourage patients to make one change at a time with subsequent goals added at follow-up appointments; focus on the changes that will bring the greatest benefit, e.g. weight loss or smoking cessation.


**Connect patients to services that can assist with lifestyle changes,** including referring patients to a dietitian, providing them with a Green Prescription, or referring to programmes offered by a local PHO, DHB or Māori health provider.

### Pharmacological management of people with early onset type 2 diabetes

The approach to pharmacological management of type 2 diabetes in patients with early onset is essentially the same as for any patients with type 2 diabetes, i.e. metformin first-line, followed by other oral and injectable glucose-lowering medicines, as appropriate (also see: “Managing type 2 diabetes in children and adolescents”). However, faster escalation of treatments may be required and lower targets for glycaemic control are justified.<sup>25</sup> Patients with early onset type 2 diabetes can have a more rapid increase in HbA<sub>1c</sub> levels, despite

treatment, and are likely to require more frequent dose increases, use of multiple oral medicines or earlier addition of insulin than older patients with type 2 diabetes.<sup>26</sup> Effective communication and engagement with patients and their whānau/family in regards to the importance of adhering to their prescribed medicines is of particular importance in this age group. Reinforce that if they can gain control with assertive treatment and lifestyle, it may be possible to dial treatment back over time.

 For further information on setting a HbA<sub>1c</sub> target and prescribing glucose-lowering medicines for patients with type 2 diabetes, see: “Type 2 diabetes management toolbox: from lifestyle to insulin”, Page 6

 For further information on initiating insulin, see: “Initiating insulin for people with type 2 diabetes”, Page 34

### Metformin for patients with “pre-diabetes”

Metformin can be prescribed (unapproved indication) to reduce the risk of developing type 2 diabetes in patients at high risk (e.g. HbA<sub>1c</sub> of 46 – 49 mmol/mol), but should be considered an adjunct treatment in addition to changes in diet and activity levels.<sup>17</sup> Metformin reduces the risk of developing type 2 diabetes by approximately one-third after three years, and approximately 20% after ten years, compared to a placebo medicine in patients at high risk.<sup>27</sup>

### Managing type 2 diabetes in children and adolescents

Children and adolescents with type 2 diabetes are typically managed in secondary care, with primary care providing additional support to the patient and their whānau/family. A HbA<sub>1c</sub> target of < 48 mmol/mol is recommended for children and adolescents to reduce the long-term risk of developing diabetes complications.<sup>12</sup> Metformin is the first-line pharmacological treatment, up to a maximum dose of 2 g, daily.<sup>12</sup> If the patient’s HbA<sub>1c</sub> level is ≥ 69 mmol/mol or they are symptomatic at diagnosis, insulin is initiated in addition to metformin. Once HbA<sub>1c</sub> levels have reduced to target, insulin can be titrated down and withdrawn.<sup>12</sup>

Currently, metformin and insulin are the only medicines approved in New Zealand for use in people with type 2 diabetes aged < 18 years.<sup>12</sup> Other glucose-lowering medicines approved for use in adults, e.g. empagliflozin, dulaglutide, vildagliptin, sulfonylureas and pioglitazone, may be considered for children and adolescents with type 2 diabetes, on the recommendation of a paediatric endocrinologist.<sup>12</sup>

### Regular review is essential to minimise the risk of long-term diabetes complications

Despite being young, people diagnosed with diabetes at an early age may already have complications and should have their retinal, foot, renal and cardiovascular health fully

assessed and managed at diagnosis. Also consider associated co-morbidities, such as sleep apnoea or non-alcoholic fatty liver disease.

### Managing cardiovascular and renal risk

Cardiovascular and renal diseases are the main causes of early mortality in people with type 2 diabetes, and preventing the onset or progression of these conditions in young people should be a focus of management.<sup>28</sup> Lifestyle changes can improve markers of cardiovascular risk, such as blood pressure and lipid levels, however, pharmacological treatment should be initiated if lifestyle changes result in insufficient improvements, or if the patient's CVD risk is high.

👁 For further information on managing cardiovascular and renal risk in patients with type 2 diabetes, see: [www.health.govt.nz/publication/cardiovascular-disease-risk-assessment-and-management-primary-care](http://www.health.govt.nz/publication/cardiovascular-disease-risk-assessment-and-management-primary-care)

👁 An online calculator for determining the risk of cardiovascular and renal disease in patients with type 2 diabetes is available at: [www.nzssd.org.nz/cvd\\_renal/](http://www.nzssd.org.nz/cvd_renal/)

### Transition stages are a risk time for worsening diabetes management

Guidelines recommend that all adolescents with type 2 diabetes transition to an adult diabetes service.<sup>12</sup> This transition period can be a time when issues with appointment attendance, adherence to medicines and lifestyle interventions, worsening glycaemic control, acute and chronic complications arise.<sup>12</sup> Primary care should establish who is responsible for the patient's diabetes care and ensure that they are regularly followed up, including reviews of their glycaemic control, medicines regimen, mental health and wellbeing, and undergo a diabetes review annually.


👁 For further information on the annual diabetes review, see: "The annual diabetes review: screening, monitoring and managing complications", Page 44

---

**Acknowledgement:** This article is a revision of an original article published by bpac<sup>nz</sup> in 2018. The original article was reviewed by **Professor Tim Cundy**, Endocrinologist and Diabetes Specialist, Auckland DHB and School of Medicine, University of Auckland and **Dr Paul Drury**, Clinical Advisor: Diabetes, Ministry of Health

N.B. Expert reviewers do not write the articles and are not responsible for the final content. bpac<sup>nz</sup> retains editorial oversight of all content.

---



**Table 1:** Using language which can help avoid blame when discussing diabetes. Adapted from the American Association of Diabetes Educators and American Diabetes Association.<sup>29</sup>

Language/tone of conversation which may have negative connotations	Suggestions for replacement concepts and phrases	Things to consider
<p><b>Compliance/adherence</b></p> <p>e.g. "You must take metformin twice a day"</p>	<p>Concepts such as engagement, participation, involvement</p> <p>Explain the benefits of medicine use and encourage patients to follow dosing instructions, e.g.: "Taking metformin twice a day will make it easier for you to reduce your HbA<sub>1c</sub> level than taking it less often"</p>	<p>Focus on using factual statements to emphasise how the person's health could improve by following the advice</p>
<p><b>Regimen/rules</b></p> <p>e.g. "You need to do 30 minutes of moderate intensity exercise per day"</p>	<p>e.g. "You're doing around 15 minutes per day of walking. This is great - do you think you could now do a bit more? Are there other types of exercise you would like to try? What are some of the things that might stop you from doing more?"</p>	<p>Encourage people to identify changes they want to make and help them to achieve those goals, rather than dictating what those changes should be and judging their progress based on what you think they should achieve</p>
<p><b>Control:</b></p> <p>e.g. "Your diabetes is not well-controlled"</p>	<p>Instead of referring to "good/bad control" explain what HbA<sub>1c</sub> level is being aimed for and the effects of the current approach to treatment:</p> <p>e.g. "Your HbA<sub>1c</sub> level is 70 mmol/mol. That is an improvement, but how about we make another goal to try to get it even lower."</p> <p>"We started metformin last time, but it is not bringing down your HbA<sub>1c</sub> levels enough. We might need to increase the dose."</p>	<p>Control may be impossible to achieve given the body's systems for regulating glucose levels are failing. Try to focus on the underlying physiology and what a patient is doing well.</p>
<p><b>Can't/shouldn't/don't</b></p> <p>e.g. "Don't have fizzy drinks"</p>	<p>"Have you tried..."</p> <p>"Would you consider..."</p> <p>"I've found what has worked for other people is..."</p> <p>e.g. encourage alternatives, such as "try water with a slice of lemon"</p>	<p>This type of statement (can't/shouldn't/don't) can make people feel they are being given orders</p>
<p><b>Lacking motivation or unwilling to engage</b></p> <p>e.g. "So you are not willing to start insulin?"</p>	<p>Focus on perceived barriers and why a patient doesn't want to proceed with a plan of action. This may lead to potential solutions.</p> <p>e.g. "From what you are saying, your main concerns around starting insulin are weight gain and the potential embarrassment of injecting yourself at work?"</p>	<p>Most people want to live a healthy life. The challenge with managing diabetes and weight is that people can feel there are barriers stopping them from changing, or may not appreciate the benefits of doing things differently. People may feel it is not worth the effort or is unachievable.</p>



## References

1. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2014;384:766–81. doi:10.1016/S0140-6736(14)60460-8
2. PricewaterhouseCoopers New Zealand. The economic and social cost of type 2 diabetes. 2021. Available from: <https://healthierlives.co.nz/wp-content/uploads/Economic-and-Social-Cost-of-Type-2-Diabetes-FINAL-REPORT.pdf> (Accessed Mar, 2021).
3. Ministry of Health NZ. Living well with diabetes. Ministry of Health NZ 2015. Available from: [www.health.govt.nz/publication/living-well-diabetes](http://www.health.govt.nz/publication/living-well-diabetes) (Accessed Mar, 2021).
4. Sjardin N, Reed P, Albert B, et al. Increasing incidence of type 2 diabetes in New Zealand children <15 years of age in a regional-based diabetes service, Auckland, New Zealand: Increasing incidence of type 2 diabetes. *J Paediatr Child Health* 2018;54:1005–10. doi:10.1111/jpc.13924
5. Coppell KJ, Mann JI, Williams SM, et al. Prevalence of diagnosed and undiagnosed diabetes and prediabetes in New Zealand: findings from the 2008/09 Adult Nutrition Survey. *N Z Med J* 2013;126:23–42.
6. Huo X, Gao L, Guo L, et al. Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study. *Lancet Diabetes Endocrinol* 2016;4:115–24. doi:10.1016/S2213-8587(15)00508-2
7. Dabelea D, Stafford JM, Mayer-Davis EJ, et al. Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood. *JAMA* 2017;317:825–35. doi:10.1001/jama.2017.0686
8. Al-Saeed AH, Constantino MI, Molyneaux L, et al. An inverse relationship between age of type 2 diabetes onset and complication risk and mortality: the impact of youth-onset type 2 diabetes. *Diabetes Care* 2016;39:823–9. doi:10.2337/dc15-0991
9. Beig J, Khanolkar M, Cundy T. Type 2 diabetes in young adults in Central Auckland: demography and complications. *Intern Med J* 2018;48:67–73. doi:10.1111/imj.13623
10. Ministry of Health NZ. Cardiovascular disease risk assessment and management for primary care. Ministry of Health NZ 2018. Available from: [www.health.govt.nz/publication/cardiovascular-disease-risk-assessment-and-management-primary-care](http://www.health.govt.nz/publication/cardiovascular-disease-risk-assessment-and-management-primary-care) (Accessed Mar, 2021).
11. Sattar N, Gill JMR. Type 2 diabetes in migrant south Asians: mechanisms, mitigation, and management. *The Lancet Diabetes & Endocrinology* 2015;3:1004–16. doi:10.1016/S2213-8587(15)00326-5
12. Peña AS, Curran JA, Fuery M, et al. Screening, assessment and management of type 2 diabetes mellitus in children and adolescents: Australasian Paediatric Endocrine Group guidelines. *Medical Journal of Australia* 2020;213:30–43. doi:10.5694/mja2.50666
13. Thomas NJ, Jones SE, Weedon MN, et al. Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank. *The Lancet Diabetes & Endocrinology* 2018;6:122–9. doi:10.1016/S2213-8587(17)30362-5
14. Rogers MAM, Kim C, Banerjee T, et al. Fluctuations in the incidence of type 1 diabetes in the United States from 2001 to 2015: a longitudinal study. *BMC Med* 2017;15:199. doi:10.1186/s12916-017-0958-6
15. Ministry of Health NZ. Clinical guidelines for weight management in New Zealand adults. Ministry of Health NZ 2017. Available from: [www.health.govt.nz/publication/clinical-guidelines-weight-management-new-zealand-adults](http://www.health.govt.nz/publication/clinical-guidelines-weight-management-new-zealand-adults) (Accessed Mar, 2021).
16. Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DIRECT): an open-label, cluster-randomised trial. *Lancet* 2018;391:541–51. doi:10.1016/S0140-6736(17)33102-1
17. Ministry of Health NZ. Pre-diabetes: risk factor management. Ministry of Health NZ 2016. Available from: [www.health.govt.nz/our-work/diseases-and-conditions/diabetes/about-diabetes/pre-diabetes-and-self-management-long-term-conditions](http://www.health.govt.nz/our-work/diseases-and-conditions/diabetes/about-diabetes/pre-diabetes-and-self-management-long-term-conditions) (Accessed Jul, 2020).
18. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. *Lancet Diabetes Endocrinol* 2015;3:866–75. doi:10.1016/S2213-8587(15)00291-0
19. New Zealand Society for the Study of Diabetes (NZSSD), Ministry of Health. Type 2 diabetes management guidance. 2021. Available from: <https://t2dm.nzssd.org.nz/> (Accessed Mar, 2021).
20. Thereaux J, Lesuffleur T, Czernichow S, et al. Association between bariatric surgery and rates of continuation, discontinuation, or initiation of antidiabetes treatment 6 years later. *JAMA Surg* 2018; [Epub ahead of print]. doi:10.1001/jamasurg.2017.6163
21. Rahiri J-L, Lauti M, Harwood M, et al. Ethnic disparities in rates of publicly funded bariatric surgery in New Zealand (2009-2014): Ethnic disparities in access to bariatric surgery. *ANZ J Surg* 2018;88:E366–9. doi:10.1111/ans.14220
22. Taylor T, Wang Y, Rogerson W, et al. Attrition after acceptance onto a publicly funded bariatric surgery program. *Obes Surg* 2018;28:2500–7
23. Ministry of Health. Annual Update of Key Results 2019/20: New Zealand Health Survey. Available from: <https://www.health.govt.nz/publication/annual-update-key-results-2019-20-new-zealand-health-survey> (Accessed Mar, 2021).
24. Perri MG, Shankar MN, Daniels MJ, et al. Effect of telehealth extended care for maintenance of weight loss in rural US communities: a randomized clinical trial. *JAMA Netw Open* 2020;3:e206764. doi:10.1001/jamanetworkopen.2020.6764
25. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetologia* 2015;58:429–42. doi:10.1007/s00125-014-3460-0
26. Lascar N, Brown J, Pattison H, et al. Type 2 diabetes in adolescents and young adults. *Lancet Diabetes Endocrinol* 2018;6:69–80. doi:10.1016/S2213-8587(17)30186-9
27. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. *Lancet* 2009;374:1677–86. doi:10.1016/S0140-6736(09)61457-4
28. American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes - 2018. *Diabetes Care* 2018;41:S73–85.
29. Dickinson JK, Guzman SJ, Maryniuk MD, et al. The use of language in diabetes care and education. *Dia Care* 2017;40:1790–9. doi:10.2337/dci17-0041



This article is available online at:  
[www.bpac.org.nz/2021/diabetes-younger.aspx](http://www.bpac.org.nz/2021/diabetes-younger.aspx)